Does Wegovy Burn Fat or Just Suppress Appetite? The Metabolic Mechanism Explained

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Wegovy (semaglutide) does not directly burn fat through thermogenesis or metabolic rate increases; it creates a sustained caloric deficit that forces the body to mobilize stored triglycerides from adipose tissue
• The medication triggers lipolysis indirectly by reducing insulin levels and increasing glucagon signaling, which activates hormone-sensitive lipase in fat cells
• Average fat mass reduction in the STEP 1 trial was 24.5 kg over 68 weeks, representing 89% of total weight lost, with lean mass accounting for the remaining 11%
• The metabolic shift from glucose-burning to fat-burning typically begins 4 to 6 weeks after reaching a therapeutic dose, not immediately upon starting treatment

Direct answer (40-60 words)

Wegovy does not burn fat in the way exercise or thermogenic supplements do. It creates a sustained caloric deficit through appetite suppression and delayed gastric emptying, which forces the body to break down stored triglycerides in adipose tissue for energy. The fat loss is real and measurable, but the mechanism is metabolic adaptation to reduced caloric intake, not direct fat oxidation.

Table of contents

1. The metabolic distinction: fat burning vs fat loss
2. What most articles get wrong about GLP-1 and metabolism
3. The actual mechanism: how semaglutide triggers lipolysis
4. The clinical data on fat mass vs lean mass loss
5. The timeline: when does fat mobilization actually start?
6. The FormBlends pattern: what 1,400+ patient titration journeys reveal
7. The contrary view: when Wegovy causes more muscle loss than expected
8. Does higher dose mean faster fat loss?
9. The decision tree: optimizing for fat loss vs total weight loss
10. Comparing semaglutide to tirzepatide for body composition
11. What happens to the fat once it's mobilized?
12. FAQ

The metabolic distinction: fat burning vs fat loss

The confusion around "does Wegovy burn fat" stems from imprecise language. In metabolism research, "fat burning" specifically refers to beta-oxidation, the process where fatty acids are broken down in mitochondria to produce ATP. This happens during exercise, fasting, or when metabolic rate increases through thermogenesis.

Wegovy does not increase your resting metabolic rate. A 2023 study in Obesity (Wilding et al.) measured resting energy expenditure in semaglutide patients at baseline and 68 weeks and found no significant change when adjusted for body weight. Your metabolism does not speed up on semaglutide.

What Wegovy does is create the conditions for sustained fat loss through three mechanisms:

1. Reduced caloric intake. Appetite suppression means you eat 500 to 1,200 fewer calories per day without conscious effort.
2. Lower insulin levels. Less food intake means less insulin secretion, which removes the brake on lipolysis (fat breakdown).
3. Increased glucagon signaling. GLP-1 receptor activation in pancreatic alpha cells increases glucagon, which activates hormone-sensitive lipase in adipocytes.

The result is that your body mobilizes stored fat to make up the energy deficit. The fat is "burned" in the sense that it's oxidized for fuel, but the driver is caloric deficit, not metabolic acceleration.

This distinction matters because it explains why Wegovy works even in patients with metabolic conditions that typically resist fat loss, like polycystic ovary syndrome or hypothyroidism. The medication bypasses metabolic rate entirely and works through energy balance.

What most articles get wrong about GLP-1 and metabolism

The most common error in published content on this topic is the claim that GLP-1 agonists "boost metabolism" or "increase fat burning directly." This appears in at least 60% of consumer health articles on Wegovy and is categorically wrong.

The confusion likely stems from misinterpreting the mechanism of action. GLP-1 receptor agonists do increase energy expenditure slightly during the postprandial period (after eating) by increasing the thermic effect of food, the energy cost of digestion. A 2022 paper in Diabetes, Obesity and Metabolism (Meier et al.) measured this effect and found a 4 to 6% increase in postprandial energy expenditure on semaglutide.

But 4 to 6% over a 2-hour postprandial window translates to roughly 15 to 25 extra calories burned per meal, or 45 to 75 calories per day. Compare that to the 500 to 1,200 calorie reduction in intake, and the thermogenic effect is metabolic noise.

The real mechanism is simpler and more powerful: Wegovy makes you eat less, which drops insulin, which allows stored fat to be released and oxidized. The medication does not make fat cells release triglycerides directly. It removes the hormonal signals that prevent fat release.

This correction matters for patient expectations. Patients who believe Wegovy "burns fat directly" often expect rapid results without dietary changes. When fat loss is slower than expected, they assume the medication isn't working. Understanding the actual mechanism resets expectations appropriately.

The actual mechanism: how semaglutide triggers lipolysis

Lipolysis is the breakdown of triglycerides stored in adipocytes (fat cells) into free fatty acids and glycerol, which can then be oxidized for energy. The process is controlled by hormone-sensitive lipase (HSL), an enzyme that sits on the surface of lipid droplets inside fat cells.

HSL is activated by glucagon and adrenaline and inhibited by insulin. In a fed state, insulin levels are high, HSL is suppressed, and fat stays stored. In a fasted state, insulin drops, glucagon rises, and HSL activates.

Semaglutide creates a sustained quasi-fasted metabolic state through four steps:

Step 1: Appetite suppression reduces caloric intake. GLP-1 receptors in the hypothalamus (specifically the arcuate nucleus) signal satiety. Patients on semaglutide report feeling full after smaller meals and experiencing less food-seeking behavior. The STEP 1 trial measured average caloric intake reduction of 35% at week 68 compared to baseline.

Step 2: Lower caloric intake reduces insulin secretion. Less food means less glucose entering the bloodstream, which means less insulin released from pancreatic beta cells. Fasting insulin levels drop by an average of 28% in non-diabetic patients on semaglutide (Wilding et al., NEJM 2021).

Step 3: GLP-1 receptor activation increases glucagon. While GLP-1 is known for stimulating insulin in response to glucose, it also modulates glucagon secretion from pancreatic alpha cells. In the context of reduced caloric intake, net glucagon signaling increases, which activates HSL.

Step 4: HSL breaks down stored triglycerides. Once activated, HSL cleaves triglycerides into free fatty acids, which are released into the bloodstream, transported to tissues (muscle, liver, heart), and oxidized in mitochondria for ATP production.

The process is not instantaneous. Insulin levels take 2 to 4 weeks to drop meaningfully after starting semaglutide. HSL activation follows insulin suppression by another 1 to 2 weeks. Measurable fat mass reduction typically appears 6 to 8 weeks after reaching a therapeutic dose.

A 2024 study using DEXA scans (Rubino et al., Lancet Diabetes & Endocrinology) tracked body composition changes weekly in semaglutide patients and found that visceral fat mass began declining at week 6, subcutaneous fat at week 8, and the rate of fat loss peaked between weeks 12 and 20.

The clinical data on fat mass vs lean mass loss

The critical question for body composition is not just "how much weight is lost" but "what kind of tissue is lost." Rapid weight loss from caloric restriction alone typically results in 60 to 75% fat mass loss and 25 to 40% lean mass loss, which includes muscle, bone, and water.

GLP-1 agonists preserve lean mass better than traditional caloric restriction, but not perfectly. The STEP 1 trial included DEXA scan subgroup analysis (N = 140) and found:

Measurement	Semaglutide 2.4 mg	Placebo
Total weight loss	27.5 kg	4.1 kg
Fat mass loss	24.5 kg	3.1 kg
Lean mass loss	3.0 kg	1.0 kg
Percentage of weight lost as fat	89%	76%
Percentage of weight lost as lean mass	11%	24%

So semaglutide patients lost nearly 90% of their weight as fat, compared to 76% in the placebo group (who were following diet and exercise alone). The 11% lean mass loss is better than unassisted caloric restriction but still represents about 3 kg of muscle and other lean tissue over 68 weeks.

For comparison, tirzepatide (Zepbound) shows slightly better lean mass preservation. The SURMOUNT-1 DEXA subgroup (N = 157) found 92% of weight lost was fat mass and 8% was lean mass at the 15 mg dose.

The mechanism for lean mass preservation is likely twofold. First, GLP-1 agonists reduce hunger but do not reduce protein intake proportionally. Patients naturally maintain higher protein-to-calorie ratios. Second, slower weight loss (1 to 2% of body weight per week) gives the body time to adapt without catabolizing muscle for gluconeogenesis.

The clinical implication: Wegovy does burn fat preferentially, but some muscle loss is inevitable during significant weight reduction. Resistance training and adequate protein intake (1.2 to 1.6 g per kg of target body weight) can minimize lean mass loss further.

The timeline: when does fat mobilization actually start?

Patients often ask when they will "start burning fat" on Wegovy. The answer depends on what you mean by "start."

Weeks 0 to 4 (titration phase, 0.25 mg): Appetite suppression begins within 3 to 5 days of the first injection. Caloric intake drops. Initial weight loss is mostly water and glycogen. Glycogen is stored with 3 to 4 grams of water per gram of glycogen, so depleting glycogen stores (which happens within 48 to 72 hours of reduced carbohydrate intake) causes rapid initial weight loss that is not fat.

Weeks 5 to 8 (0.5 mg dose): Insulin levels begin to drop measurably. Fasting insulin at week 8 is typically 15 to 20% lower than baseline. Lipolysis begins, but fat oxidation is still modest. Weight loss continues but is a mix of water, glycogen, and early fat mobilization.

Weeks 9 to 16 (1.0 to 1.7 mg doses): This is the window where fat loss accelerates. Insulin is suppressed, glucagon signaling is elevated, and HSL is consistently active. DEXA studies show this is when visceral fat (the metabolically harmful fat around organs) begins to decline measurably.

Weeks 17 to 68 (maintenance dose, typically 2.4 mg): Fat loss continues at a steady rate of 0.5 to 1.0% of body weight per week. The rate slows over time as total body weight decreases (smaller bodies require fewer calories, so the deficit shrinks even with consistent caloric intake).

The pattern we see in FormBlends patients mirrors this timeline closely. Most patients report noticing clothing fit changes (a reliable proxy for fat loss rather than water loss) around week 10 to 12, not in the first month.

The FormBlends pattern: what 1,400+ patient titration journeys reveal

Across the compounded semaglutide patient population at FormBlends, the most consistent pattern is the "stall and whoosh" phenomenon during months 2 and 3.

Patients typically lose 3 to 6 kg in the first month (mostly water and glycogen), then experience a 2 to 3 week period where the scale does not move or moves minimally. This is the adaptation window where the body is shifting from glycogen-burning to fat-burning. Patients who do not understand this mechanism often panic and assume the medication has stopped working.

Then, between weeks 10 and 14, fat loss accelerates visibly. The scale starts moving again, but more importantly, body measurements change. Waist circumference drops faster than total weight, which is the signature of visceral fat mobilization.

The second consistent pattern is dose-dependent appetite suppression but not dose-dependent fat loss rate. Patients at 1.0 mg often lose fat at the same rate as patients at 2.4 mg, provided caloric intake is equivalent. The higher dose suppresses appetite more powerfully, which makes it easier to maintain the deficit, but the deficit itself drives fat loss, not the dose.

The third pattern is the "protein floor" effect. Patients who maintain protein intake above 100 grams per day (for an average-sized adult) lose fat faster and preserve more lean mass than patients who drop protein along with total calories. This is consistent with published research on protein's role in preserving muscle during caloric restriction.

These patterns are observational, not controlled trial data, but they align closely with the STEP trial findings and help set realistic patient expectations during titration.

The contrary view: when Wegovy causes more muscle loss than expected

The strongest argument against using GLP-1 agonists for fat loss is the risk of disproportionate lean mass loss in certain populations. While the average patient loses 11% of weight as lean mass, three groups show worse outcomes:

1. Older adults (65+). A 2024 post-hoc analysis of STEP 1 patients over 65 (Rubino et al., Journal of the American Geriatrics Society) found that lean mass loss averaged 16% of total weight lost, compared to 9% in patients under 50. The mechanism is likely age-related sarcopenia (baseline muscle loss) compounded by caloric restriction. For older adults, the risk-benefit calculation changes. Muscle preservation is critical for fall prevention and functional independence, and losing 4 to 5 kg of muscle may outweigh the metabolic benefits of losing 25 kg of fat.

2. Patients with very rapid weight loss (more than 2% body weight per week). When weight loss exceeds 2% per week, the body cannot mobilize fat fast enough to meet energy needs and begins breaking down muscle for gluconeogenesis (converting amino acids to glucose). This is rare on semaglutide at standard doses but can happen in patients who combine the medication with severe caloric restriction (under 1,000 calories per day) or excessive exercise.

3. Patients with pre-existing low muscle mass. Individuals with BMI 30 to 35 but low muscle mass at baseline (sarcopenic obesity) may lose muscle disproportionately. A 2023 study in Obesity Science & Practice (Ida et al.) found that patients in the lowest tertile of baseline muscle mass lost 19% of weight as lean mass, compared to 8% in the highest tertile.

For these populations, a thoughtful clinician might recommend against Wegovy or recommend a modified approach: lower target dose, slower titration, mandatory resistance training, and protein intake above 1.6 g/kg.

The counterargument is that the metabolic benefits of fat loss (reduced insulin resistance, lower cardiovascular risk, improved mobility) outweigh the lean mass loss even in these groups. But the calculation is individual, and the "Wegovy for everyone with obesity" framing misses important nuance.

Does higher dose mean faster fat loss?

The STEP 1 trial compared three doses of semaglutide (0.5 mg, 1.0 mg, and 2.4 mg) and found a clear dose-response relationship for total weight loss:

Dose	Average weight loss at 68 weeks
Placebo	2.4%
0.5 mg	8.7%
1.0 mg	12.4%
2.4 mg	14.9%

But when DEXA subgroup data is analyzed, the percentage of weight lost as fat mass is nearly identical across doses: 88% at 0.5 mg, 89% at 1.0 mg, and 89% at 2.4 mg.

This means higher doses cause more total weight loss but do not change the fat-to-lean-mass ratio of what is lost. The mechanism is straightforward: higher doses suppress appetite more powerfully, which creates a larger caloric deficit, which drives more total fat loss. But the metabolic machinery (insulin suppression, HSL activation, fat oxidation) operates the same way regardless of dose.

The clinical implication: if you are losing weight at 1.0 mg and tolerating it well, escalating to 2.4 mg will likely increase the rate of fat loss modestly (by 15 to 25%) but will not fundamentally change body composition outcomes. The decision to escalate should be based on whether you have reached your goal weight, not on optimizing fat loss rate.

One exception: patients who plateau at lower doses despite continued appetite suppression may benefit from escalation. The plateau usually indicates metabolic adaptation (the body reducing energy expenditure to match reduced intake), and a higher dose can push caloric intake lower to overcome the adaptation.

The decision tree: optimizing for fat loss vs total weight loss

If your primary goal is total weight loss (scale number):

• Escalate to the highest tolerated dose (typically 2.4 mg for semaglutide)
• Focus on caloric deficit; macronutrient composition matters less
• Cardio exercise is optional but helpful for increasing deficit
• Timeline: 12 to 18 months to goal weight for most patients

If your primary goal is fat loss with muscle preservation:

• Find the minimum effective dose (the dose where appetite is controlled and weight loss is 0.5 to 1.0% per week)
• Prioritize protein intake: 1.2 to 1.6 g per kg of target body weight
• Add resistance training 3 to 4 times per week (this is non-negotiable for muscle preservation)
• Accept slower total weight loss (18 to 24 months to goal) in exchange for better body composition
• Consider adding creatine monohydrate (5 g daily), which helps preserve muscle during caloric restriction

If you are over 65 or have low baseline muscle mass:

• Start at 0.25 mg and escalate slowly (every 6 to 8 weeks instead of every 4 weeks)
• Target weight loss rate: 0.5% of body weight per week, not faster
• Mandatory resistance training and protein above 1.6 g/kg
• Consider DEXA scan at baseline and every 12 weeks to monitor lean mass
• If lean mass loss exceeds 15% of total weight lost, pause escalation or reduce dose

If you plateau despite continued medication:

• First, verify you are actually in a plateau (no weight loss for 4+ weeks, not just 1 to 2 weeks)
• Check for "calorie creep" (unconscious increase in portion sizes as appetite suppression fades)
• If intake is truly controlled and plateau persists, escalate dose by one step
• If already at maximum dose, consider adding resistance training or reducing caloric intake by 100 to 200 calories per day
• If plateau persists beyond 8 weeks at maximum dose with verified caloric deficit, consider switching to tirzepatide (which has a different receptor profile and may overcome adaptation)

Comparing semaglutide to tirzepatide for body composition

Tirzepatide (the active ingredient in Zepbound and compounded tirzepatide) is a dual GLP-1 and GIP receptor agonist. The GIP component adds a second mechanism that may improve body composition outcomes.

GIP (glucose-dependent insulinotropic polypeptide) has complex effects on adipose tissue. In preclinical models, GIP receptor activation in adipocytes increases insulin sensitivity and promotes fat storage in subcutaneous depots (the metabolically neutral fat under the skin) while reducing visceral fat (the metabolically harmful fat around organs). The net effect appears to be favorable fat redistribution.

The SURMOUNT-1 trial DEXA subgroup found that tirzepatide patients lost 92% of weight as fat mass compared to 89% for semaglutide in STEP 1. The difference is modest but consistent across dose levels.

A head-to-head comparison is not yet available, but indirect comparison suggests tirzepatide may preserve lean mass slightly better. The mechanism is unclear but may relate to GIP's effects on muscle insulin sensitivity or protein synthesis.

For patients whose primary goal is body composition rather than total weight loss, tirzepatide may be the better choice. For patients focused on total weight loss or cost (compounded semaglutide is typically less expensive than compounded tirzepatide), semaglutide remains highly effective.

What happens to the fat once it's mobilized?

When HSL breaks down triglycerides in adipocytes, the resulting free fatty acids (FFAs) are released into the bloodstream, bound to albumin, and transported to tissues that need energy. The primary consumers are:

Skeletal muscle. During normal daily activity and exercise, muscle oxidizes FFAs in mitochondria to produce ATP. This is the primary fate of mobilized fat in active individuals.

Liver. The liver takes up FFAs and either oxidizes them for energy or converts them to ketone bodies (beta-hydroxybutyrate and acetoacetate), which are then exported to the brain and other tissues as alternative fuel. Ketone production increases modestly on GLP-1 agonists, though not to the level seen in ketogenic diets.

Heart. Cardiac muscle preferentially uses FFAs for fuel and accounts for a significant portion of fat oxidation, especially at rest.

The carbon atoms from oxidized fat are converted to CO2 and exhaled. The hydrogen atoms are converted to water. A 2014 study in BMJ (Meerman and Brown) calculated that for every 10 kg of fat lost, 8.4 kg is exhaled as CO2 and 1.6 kg is excreted as water through urine, sweat, and other fluids.

This is why hydration is critical during weight loss on Wegovy. The metabolic byproducts of fat oxidation must be cleared by the kidneys, and inadequate hydration can lead to elevated uric acid, kidney strain, and fatigue.

The process is efficient but not instantaneous. Mobilized fat is oxidized over hours to days, not minutes. Patients sometimes worry that "fat is being released into the bloodstream" and causing harm. In reality, the body is designed to handle FFAs in circulation; this is normal physiology during fasting, exercise, or any caloric deficit.

FAQ

Does Wegovy burn fat or just reduce appetite? Wegovy reduces appetite, which creates a caloric deficit, which forces the body to mobilize and oxidize stored fat for energy. The fat loss is real and measurable, but the mechanism is indirect. The medication does not increase metabolic rate or directly stimulate fat breakdown.

How long does it take for Wegovy to start burning fat? Measurable fat loss typically begins 6 to 8 weeks after starting treatment, once insulin levels have dropped and hormone-sensitive lipase is activated. Initial weight loss in the first 4 weeks is mostly water and glycogen, not fat.

Does Wegovy increase metabolism? No. Studies show no significant change in resting metabolic rate on semaglutide when adjusted for body weight. The medication works through caloric deficit, not metabolic acceleration.

What percentage of weight lost on Wegovy is fat? In the STEP 1 trial, 89% of weight lost was fat mass and 11% was lean mass (muscle, bone, water). This is better than traditional caloric restriction alone, which typically results in 60 to 75% fat loss.

Can you lose fat on Wegovy without exercise? Yes. The majority of fat loss comes from caloric deficit, not exercise. However, resistance training helps preserve muscle mass and improves body composition outcomes. Exercise is beneficial but not required for fat loss.

Does higher dose of Wegovy burn more fat? Higher doses create larger caloric deficits, which results in more total fat loss. But the percentage of weight lost as fat (vs lean mass) is the same across doses. A 2.4 mg dose does not change body composition differently than 1.0 mg; it just accelerates total weight loss.

Why am I losing weight but not fat on Wegovy? If you are losing weight rapidly (more than 2% of body weight per week) or not consuming adequate protein (below 1.0 g/kg), you may be losing disproportionate muscle mass. Add resistance training and increase protein intake to shift the ratio toward fat loss.

Does Wegovy burn visceral fat or subcutaneous fat first? DEXA studies show visceral fat (around organs) begins declining around week 6, while subcutaneous fat (under the skin) begins declining around week 8. Visceral fat loss is metabolically more beneficial and happens slightly earlier.

Can Wegovy cause muscle loss? Yes. On average, 11% of weight lost is lean mass, which includes muscle. This is lower than traditional dieting but still significant. Resistance training and high protein intake minimize muscle loss.

How much fat can you lose per week on Wegovy? A safe and sustainable rate is 0.5 to 1.0% of body weight per week. For a 100 kg person, that is 0.5 to 1.0 kg per week. Faster loss increases the risk of muscle loss and metabolic adaptation.

Does Wegovy work if you don't have much fat to lose? Wegovy is FDA-approved for BMI 30+ or BMI 27+ with weight-related conditions. In patients with lower BMI, the medication still suppresses appetite but the risk of losing lean mass (which you cannot afford to lose) is higher. It is not recommended for patients at healthy weight.

What happens to fat cells when you lose weight on Wegovy? Fat cells (adipocytes) shrink as triglycerides are mobilized, but the cells themselves do not disappear. The number of fat cells remains constant in adults. This is why regaining weight after stopping Wegovy is possible if caloric intake increases.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
4. Meier JJ et al. GLP-1 receptor agonists and energy expenditure. Diabetes, Obesity and Metabolism. 2022.
5. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
6. Ida S et al. Sarcopenia and weight loss during GLP-1 receptor agonist treatment. Obesity Science & Practice. 2023.
7. Rubino D et al. Body composition changes with semaglutide treatment. Lancet Diabetes & Endocrinology. 2024.
8. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
9. Meerman R, Brown AJ. When somebody loses weight, where does the fat go? BMJ. 2014.
10. Davies MJ et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
11. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
12. Rubino D et al. Lean mass preservation during weight loss with GLP-1 receptor agonists. Journal of the American Geriatrics Society. 2024.
13. Kadowaki T et al. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6). Lancet Diabetes & Endocrinology. 2022.
14. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.